JNJ-26481585

• CAT Number: I005270
• CAS Number: 875320-29-9
• Molecular Formula: C₂₁H₂₆N₆O₂
• Molecular Weight: 394.21
• Purity: ≥95%
• Target: HDAC
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 0.11 nM (HDAC1), 0.33 nM (HDAC2), 0.64 nM (HDAC4), 0.46 nM (HDAC10), 0.37 nM (HDAC11) [1]
• IUPAC Name: N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide
• InChI: InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)
• InChIKey: PAWIYAYFNXQGAP-UHFFFAOYSA-N
• SMILES: CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO

JNJ-26481585 (Cat.No:I005270) is a novel, orally bioavailable histone deacetylase (HDAC) inhibitor. It selectively targets HDAC1, HDAC2, and HDAC3 enzymes, resulting in the modulation of gene expression and potential antitumor activity. Preclinical studies have shown promising results in various cancer types, making JNJ-26481585 a potential candidate for cancer therapy.

Reference

[1]. Venugopal B, et al. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res. 2013 Aug 1;19(15):4262-4272.
[2]. Carol H, et al. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2014 Feb;61(2):245-252.